ADRX-0706 is a Nectin-4 ADC being evaluated in the Phase 1b portion of an ongoing Phase 1a/b clinical trial (NCT06036121) for the treatment of select advanced solid tumors, including cervical cancer.
SAN DIEGO, April 23, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other ...
Enhancing prognostic precision in bladder cancer: AI-driven tumor microenvironment analysis from H&E images. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...
Researchers from Adcentrx Therapeutics Inc. recently reported preclinical data for the Nectin-4-targeting antibody-drug conjugate (ADC) ADRX-0706, currently in phase I development for the treatment of ...
27,121 people played the daily Crossword recently. Can you solve it faster than others?27,121 people played the daily Crossword recently. Can you solve it faster than others?
SAN DIEGO, May 6, 2025 /PRNewswire/ -- Adcentrx Therapeutics ("Adcentrx"), a clinical-stage biotechnology company redefining Antibody-Drug Conjugate (ADC) therapies for cancer treatment and other life ...
Interim results from Phase 1a dose escalation to be presented Data provide clinical proof of concept for Adcentrx's novel technology platform; highlight unique opportunity for ADRX-0706 to address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results